Combining Transarterial Chemoembolization with Sorafenib Improves Survival in Selected Patients with Hepatocellular Carcinoma and Extrahepatic Spread: A Multicenter Real-World Study

This real-world study demonstrates that in carefully selected patients with HCC-EHS, a combination of TACE and sorafenib provides significantly better tumor control and survival outcomes than TACE monotherapy. These findings suggest that an integrated therapeutic strategy, which aggressively manages the intrahepatic disease in conjunction with systemic therapy, can improve outcomes in this challenging-to-treat population and warrants validation in prospective studies.